Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Galapagos

3 Biotech Stocks Climbing the Ranks to Watch

The biotech industry is thriving on growing applications across sectors from healthcare to agriculture, favorable government funding and policies, and technological breakthroughs. Amid this backdrop, quality biotech stocks UroGen Pharma (URGN), Foghorn Therapeutics (FHTX), and Galapagos (GLPG) might be ideal additions to one’s watchlist. Read on….

Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral

Here's a roundup of top developments in the biotech space over the last 24 hours:

Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field

Galapagos (NASDAQ:GLPG) agreed to acquire CellPoint and AboundBio in an all-cash transaction propelling into next-generation cell therapy while significantly broadening its portfolio and capabilities. Galapagos will pay an upfront amount of €125 million for CellPoint, an additional €100 million to be paid upon achieving certain milestones, and $14 million for AboundBio. Galapagos said…

Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine

Scipher Medicine announced that Galapagos (NASDAQ:GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher's Spectra platform. In August 2020, Galapagos and Scipher Medicine agreed to jointly validate a suite of novel IBD targets discovered by Spectra. Galapagos has the exclusive option to in-license certain validated preclinical targets…

Losses widen at e-therapeutics but CEO hails 'landmark year' of progress

Ali Mortazavi said it had been a transformative year for the computational drug discovery specialist and that he was 'extremely pleased' with progress

Birmingham Post

inkl

Read news from The Economist, FT, and more,
with one subscription

E-therapeutics receives cash payments in key milestone with European partner

E-therapeutics receives cash payments in key milestone with European partner

The drug innovator says it has completed all initial milestones in its partnership with Belgian firm Galapagos NV

Birmingham Post

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

B of A Securities

Coinbase Global

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

353,467 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play